AstraZeneca Plc Chief Executive Pascal Soriot has said that the company is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine.
Several scientists have raised doubts about the robustness of results showing the shot was 90 percent effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose. "The reason we had the half-dose is serendipity," Mene Pangalos, the head of AstraZeneca's non-oncology research and development, told Reuters.A larger group who had received two full doses, as planned, resulted in an efficacy read-out of 62 percent, leading to an overall efficacy of 70 percent across both dosing patterns.
They soon noticed expected side effects such as fatigue, headaches or arm aches were milder than expected, he said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.